Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled amikacin for prevention of ventilator-associated pneumonia in mechanically ventilated ICU adults
IRCT20260614069780N1Phase 3Recruiting
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of amikacin in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Occurrence of ventilator-associated pneumonia, Time to ventilator-associated pneumonia occurrence and 7 more. Started Apr 2026; status: recruiting.
02
Drugs
amikacin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on IRCT20260614069780N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260614069780N1.